📰 Nasdaq Advm News
Nasdaq Advm News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Advm. Real-time updates on events, politics, business and more.
May 3, 2024
HC Wainwright initiated coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q1 2024 earnings at ($1.23) EPS, Q2 2024 earnings […]
May 3, 2024
Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its target price trimmed by Mizuho from $40.00 to $22.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research analysts also recently issued reports on the company. StockNews.com raised Adverum Biotechnologies […]
March 26, 2024
StockNews.com upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday. A number of other equities analysts have also recently commented on ADVM. Mizuho lifted their price target on Adverum Biotechnologies from $20.00 to $40.00 and gave the stock […]
February 28, 2024
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Adverum Biotechnologies and Agenus’ […]
February 28, 2024
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability. Risk and Volatility Adverum Biotechnologies has a beta […]
January 10, 2024
Marquette Asset Management LLC decreased its stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) by 50.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 60,120 shares of the biotechnology company’s stock after selling 61,273 shares during the period. Marquette Asset Management LLC owned […]
December 10, 2023
Commodore Capital LP grew its holdings in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) by 100.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,000,000 shares of the biotechnology company’s stock after purchasing an additional 5,000,000 shares during the quarter. Adverum […]
November 4, 2023
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...
October 4, 2023
BML Capital Management LLC reduced its stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) by 27.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,157,179 shares of the biotechnology company’s stock after selling 1,910,000 shares during the period. Adverum Biotechnologies makes up […]
September 26, 2023
- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically...